Last update 18 Nov 2026

Revumenib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Revumenib Citrate, 瑞武美尼, SNDX 5613
+ [4]
Target
Action
inhibitors
Mechanism
menin inhibitors(Menin inhibitors)
Originator Organization
Inactive Organization-
License Organization-
Drug Highest PhaseApproved
First Approval Date
United States (15 Nov 2024),
RegulationPriority Review (United States), Breakthrough Therapy (United States), Fast Track (United States), Orphan Drug (United States), Orphan Drug (European Union)
Login to view timeline

Structure/Sequence

Molecular FormulaC32H47FN6O4S
InChIKeyFRVSRBKUQZKTOW-YOCNBXQISA-N
CAS Registry2169919-21-3

External Link

KEGGWikiATCDrug Bank
D12728D12729--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Acute myeloid leukemia with mutated NPM1
United States
24 Oct 2025
Acute Leukemia with a KMT2A Translocation
United States
15 Nov 2024
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute Myeloid LeukemiaPhase 3
Argentina
25 Nov 2025
Acute Myeloid LeukemiaPhase 3
Australia
25 Nov 2025
Acute Myeloid LeukemiaPhase 3
Austria
25 Nov 2025
Acute Myeloid LeukemiaPhase 3
Belgium
25 Nov 2025
Acute Myeloid LeukemiaPhase 3
Brazil
25 Nov 2025
Acute Myeloid LeukemiaPhase 3
Canada
25 Nov 2025
Acute Myeloid LeukemiaPhase 3
France
25 Nov 2025
Acute Myeloid LeukemiaPhase 3
Germany
25 Nov 2025
Acute Myeloid LeukemiaPhase 3
Greece
25 Nov 2025
Acute Myeloid LeukemiaPhase 3
Hungary
25 Nov 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
Acute myeloid leukemia with mutated NPM1
First line
NPM1 mutation | KMT2A rearrangement | NUP98 rearrangement
35
Revumenib 220 mg or 110 mg + strong CYP3A4 inhibitor, in combination with cytarabine and daunorubicin/idarubicin
lagykuwgym(ahlunrblqg) = kouhzpiccv dxhvmyzhdx (vpmkfmlktl )
Positive
12 Dec 2026
Revumenib 270 mg or 160 mg + strong CYP3A4 inhibitor, in combination with cytarabine and daunorubicin/idarubicin
lagykuwgym(ahlunrblqg) = nnvdarcbnu dxhvmyzhdx (vpmkfmlktl )
Phase 1/2
91
(baseline transfusion dependent)
bijkjmmqhy(unpvjlnxhp) = njaiaxrxvk skzgpxvxwo (dkzqttqynw )
Positive
12 Dec 2026
(baseline transfusion independent)
bijkjmmqhy(unpvjlnxhp) = onbumdnpvk skzgpxvxwo (dkzqttqynw )
Not Applicable
47
mcnmeagwib(wzbwcimzhx) = lkdyuilfxk wmmndpsmuh (isgmazmemo )
Positive
12 Dec 2026
Revumenib + other drugs
mcnmeagwib(wzbwcimzhx) = xgxoeuquyp wmmndpsmuh (isgmazmemo )
Phase 1/2
24
ybqxavuthu(gkwuxkkatu) = gljlqkvkte zxpmygstqn (naxrdegobr )
Positive
12 Dec 2026
Phase 1/2
30
buoemeteif(taavdeqlfq) = fjtntfuukc rvxzfsqsbf (vzjpojtbfz )
Positive
12 Dec 2026
Not Applicable
32
twmdqteujv(haazuotdcc) = Five pts had G3 QTcF prolongation (19%; 3 interruptions, 1 reduction) although 2/5 met G3 QTcF criteria only due to a >60 msec increase from baseline. lhpxtadpga (tfjsgzczwa )
Positive
12 Dec 2026
(R/R disease)
Phase 1/2
Refractory Acute Leukemia
NPM1 mutation | KMT2A translocation
59
xsxkxxkzzz(chgoakerre) = Grade 3 QTcF prolongation occurred in 11 (19%) pts wzyhmjkodf (vfmxqwpzht )
Positive
12 Dec 2026
Phase 1
acute leukemia
Maintenance
KMT2A rearrangements | NPM1 mutations
18
Revumenib 160mg q12h
uyuurroavz(dktyilplsb) = The most common ≥ grade (G) 3 treatment-emergent adverse events (TEAE) were hematologic: G3 neutropenia (DL1, n=3; DL2, n=6), thrombocytopenia (DL2, n=8), anemia (DL1, n=1, DL2, n=3); G4 were limited to DL2 (one neutropenia and one thrombocytopenia). Hematologic toxicities were reversible and managed with growth factors and dose interruption/reduction. The most common non-hematologic G3 TEAEs included QT interval prolongation (DL1, n=1, DL2, n=1) and nausea/emesis (DL2, n=3). zdzrsxcrcu (eaztfelwvc )
Positive
12 Dec 2026
Phase 1
Acute myeloid leukemia with mutated NPM1
NPM1-mutated | KMT2A-rearranged
82
sozhxlsiry(rlafbyvndm) = Differentiation Syndrome occurred in 13 (16%) pts (G>3: 6%), was similar in KMT2Ar vs. NPM1m: (19% vs. 15%), and higher in DL1 vs. DL2 (23% vs. 10%). ofrivetjcv (sjegijuvrx )
Positive
12 Dec 2026
Phase 2
Acute Myeloid Leukemia
NPM1 mutation | KMT2A rearrangement
28
lqcwsyklco(fcamtjcgzu) = The most common grade ≥3 adverse events were thrombocytopenia (50%), febrile neutropenia (46%) and neutropenia (36%). vstuzzqhzj (rrnhaertew )
Positive
12 Dec 2026
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free